Treatment of active lupus nephritis with the novel immunosuppressant 15-deoxyspergualin: An open-label dose escalation study

Arthritis Research and Therapy

Volumn 13, Issue 2, 2011, Pages

  Lorenz, Hanns Martin ^a   Schmitt, Wilhelm H ^b   Tesar, Vladimir ^c   Müller Ladner, Ulf ^d   Tarner, Ingo ^d   Hauser, Ingeborg A ^e   Hiepe, Falk ^f   Alexander, Tobias ^f   Woehling, Heike ^g   Nemoto, Kyuichi ^h   Heinzel, Peter A ^h  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c CHARLES UNIVERSITY   (Czech Republic)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g Dabio GmbH   (Germany)

^h Euro Nippon Kayaku GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISONE; RITUXIMAB; GUANIDINE DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; BRONCHITIS; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DENTAL CARIES; DISEASE ACTIVITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; GASTROENTERITIS; GASTROINTESTINAL DISEASE; HERPES SIMPLEX; HERPES ZOSTER; HISTOPATHOLOGY; HUMAN; INFECTION; INSECT BITE; LABYRINTHITIS; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; ONYCHOMYCOSIS; OTITIS MEDIA; PATIENT COMPLIANCE; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROTEINURIA; RESPIRATORY TRACT INFECTION; RHINITIS; RHINOPHARYNGITIS; SAFETY OF ESTROGENS IN LUPUS ERYTHEMATOSUS NATIONAL ASSESSMENT SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX; SCORING SYSTEM; SIALOADENTITIS; SKIN INFECTION; THRUSH; TINEA INFECTION; TONSILLITIS; TOOTH INFECTION; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VAGINA CANDIDIASIS; CLINICAL TRIAL; PILOT STUDY;

ADULT; FEMALE; GUANIDINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; PILOT PROJECTS; YOUNG ADULT;

EID: 79952088871     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3268     Document Type: Article

References (43)

1. Balow JE. Choosing treatment for proliferative lupus nephritis. Arthritis Rheum 2002, 46:1981-1983. 10.1002/art.10466, 12209498.
2. Falk JR. Treatment of lupus nephritis - a work in progress. N Engl J Med 2000, 343:1182-1183. 10.1056/NEJM200010193431610, 11036127.
3. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005, 353:2219-2228. 10.1056/NEJMoa043731, 16306519.
4. Dooley MA, Hogan S, Jennette C, Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int 1997, 51:1188-1195. 10.1038/ki.1997.162, 9083285.
5. Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Pando J, Steinberg AD, Gourley MF, Klippel JH, Balow JE, Boumpas DT. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002, 46:995-1002. 10.1002/art.10142, 11953977.
6. Boumpas DT, Austin HA, Fessler BJ, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med 1995, 122:940-950.
7. Faurschou M, Sorensen IJ, Mellemkjaer L, Loft AG, Thomsen BS, Tvede N, Baslund B. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008, 35:100-105.
8. Knight A, Askling J, Granath F, Sparen P, Ekbom A. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis 2004, 63:1307-1311. 10.1136/ard.2003.019125, 1754772, 15130900.
9. Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nölle B, Heller M, Gross WL. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000, 43:1021-1032. 10.1002/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J, 10817555.
10. Kaufman DB. 15-Deoxyspergualin in experimental transplant models: a review. Transplant Proc 1996, 28:868-870.
11. Tepper MA, Petty B, Bursuker I, Pasternak RD, Cleaveland J, Spitalny GL, Schacter B. Inhibition of antibody production by the immunosuppressive agent, 15-deoxyspergualin. Transplant Proc 1991, 23:328-331.
12. Fujii H, Takada T, Nemoto K, Yamashita T, Abe F, Fujii A, Takeuchi T. Deoxyspergualin directly suppresses antibody formation in vivo and in vitro. J Antibiot 1990, 43:213-219.
13. Pai LH, Fitzgerald DJ, Tepper M, Schacter B, Spitalny G, Pastan I. Inhibition of antibody response to Pseudomonas exotoxin and an immunotoxin containing Pseudomonas exotoxin by 15-deoxyspergualin in mice. Cancer Res 1990, 50:7750-7753.
14. Dhingra K, Fritsche H, Murray JL, LoBuglio AF, Khazaeli MB, Kelley S, Tepper MA, Grasela D, Buzdar A, Valero V. Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. Cancer Res 1995, 55:3060-3070.
15. Morikawa K, Oseko F, Morikawa S. The suppressive effect of deoxyspergualin on the differentiation of human B lymphocytes maturing into immunoglobulin-producing cells. Transplantation 1992, 54:526-531. 10.1097/00007890-199209000-00026, 1329279.
16. Morikawa K, Nemoto K, Miyawaki T, Morikawa S. Deoxyspergualin preferentially inhibits the growth and maturation of anti-CD40-activated surface IgD+ B lymphocytes. Clin Exp Immunol 1998, 112:495-500. 10.1046/j.1365-2249.1998.00602.x, 1904992, 9649221.
17. Tepper MA. Deoxyspergualin. Mechanism of action studies of a novel immunosuppressive drug. Ann N Y Acad Sci 1993, 696:123-132. 10.1111/j.1749-6632.1993.tb17147.x, 8109823.
18. Hoeger PH, Tepper MA, Faith A, Higgins JA, Lamb JR, Geha RS. Immunosuppressant deoxyspergualin inhibits antigen processing in monocytes. J Immunol 1994, 153:3908-3916.
19. Panjwani N, Akbari O, Garcia S, Brazil M, Stockinger B. The HSC73 molecular chaperone: involvement in MHC class II antigen presentation. J Immunol 1999, 163:1936-1942.
20. Nadler SG, Dischino DD, Malacko AR, Cleaveland JS, Fujihara SM, Marquardt H. Identification of a binding site on Hsc70 for the immunosuppressant 15-deoxyspergualin. Biochem Biophys Res Commun 1998, 253:176-180. 10.1006/bbrc.1998.9775, 9875240.
21. Nadler SG, Eversole AC, Tepper MA, Cleaveland JS. Elucidating the mechanism of action of the immunosuppressant 15-deoxyspergualin. Ther Drug Monit 1995, 17:700-703. 10.1097/00007691-199512000-00026, 8588244.
22. Nadler SG, Tepper MA, Schacter B, Mazzucco CE. Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins. Science 1992, 258:484-486. 10.1126/science.1411548, 1411548.
23. Tepper MA, Nadler SG, Esselstyn JM, Sterbenz KG. Deoxyspergualin inhibits kappa light chain expression in 70Z/3 pre-B cells by blocking lipopolysaccharide-induced NF-kappa B activation. J Immunol 1995, 155:2427-2436.
24. Nishimura K, Ohki Y, Fukuchi-Shimogori T, Sakata K, Saiga K, Beppu T, Shirahata A, Kashiwagi K, Igarashi K. Inhibition of cell growth through inactivation of eukaryotic translation initiation factor 5A (eIF5A) by deoxyspergualin. Biochem J 2002, 363:761-768. 10.1042/0264-6021:3630761, 1222529, 11964177.
25. Thomas JM, Contreras JL, Jiang XL, Eckhoff DE, Wang PX, Hubbard WJ, Lobashevsky AL, Wang W, Asiedu C, Stavrou S, Cook WJ, Robbin ML, Thomas FT, Neville DM. Peritransplant tolerance induction in macaques: early events reflecting the unique synergy between immunotoxin and deoxyspergualin. Transplantation 1999, 68:1660-1673. 10.1097/00007890-199912150-00009, 10609942.
26. Sugawara A, Torigoe T, Tamura Y, Kamiguchi K, Nemoto K, Oguro H, Sato N. Polyamine compound deoxyspergualin inhibits heat shock protein-induced activation of immature dendritic cells. Cell Stress Chaperones 2009, 14:133-139. 10.1007/s12192-008-0064-y, 2727995, 18686015.
27. Nemoto K, Hayashi M, Sugawara Y, Ito J, Abe F, Takita T, Nakamura T, Takeuchi T. Biological activities of deoxyspergualin in autoimmune disease mice. J Antibiot 1988, 41:1253-1259.
28. Okubo M, Inoue K, Umetani N, Sato N, Kamata K, Masaki Y, Uchiyama T, Yan XJ, Aoyagi T, Shirai T. Lupus nephropathy in New Zealand F1 hybrid mice treated by (-)15-deoxyspergualin. Kidney Int 1988, 34:467-473. 10.1038/ki.1988.204, 3199666.
29. Ito S, Ueno M, Arakawa M, Saito T, Aoyagi T, Fujiwara M. Therapeutic effect of 15-deoxyspergualin on the progression of lupus nephritis in MRL mice. I. Immunopathological analyses. Clin Exp Immunol 1990, 81:446-453. 10.1111/j.1365-2249.1990.tb05354.x, 1534978, 2397613.
30. Birck R, Newman M, Braun C, Neumann I, Nemoto K, Yard B, Waldherr R, van der Woude FJ. 15-Deoxyspergualin and cyclophosphamide, but not mycophenolate mofetil, prolong survival and attenuate renal disease in a murine model of ANCA-associated crescentic nephritis. Nephrol Dial Transplant 2006, 21:58-63. 10.1093/ndt/gfi070, 16141461.
31. Saiga K, Yoshida M, Nakamura I, Toyoda E, Tokunaka K, Morohashi H, Abe F, Nemoto K, Nose M. Evaluation of the ameliorative effects of immunosuppressants on crescentic glomerulonephritis in SCG/Kj mice. Int Immunopharmacol 2008, 8:1183-1189. 10.1016/j.intimp.2008.04.005, 18602063.
32. Amemiya H, Suzuki S, Ota K, Takahashi K, Sonoda T, Ishibashi M, Omoto R, Koyama I, Dohi K, Fukuda Y. A novel rescue drug, 15-deoxyspergualin. First clinical trials for recurrent graft rejection in renal recipients. Transplantation 1990, 49:337-343. 10.1097/00007890-199002000-00022, 2407004.
33. Okubo M, Tamura K, Kamata K, Tsukamoto Y, Nakayama Y, Osakabe T, Sato K, Go M, Kumano K, Endo T. 15-Deoxyspergualin "rescue therapy" for methylprednisolone-resistant rejection of renal transplants as compared with anti-T cell monoclonal antibody (OKT3). Transplantation 1993, 55:505-508. 10.1097/00007890-199303000-00010, 8456469.
34. Birck R, Warnatz K, Lorenz HM, Choi M, Haubitz M, Grünke M, Peter HH, Kalden JR, Göbel U, Drexler JM, Hotta O, Nowack R, Van Der Woude FJ. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 2003, 14:440-447. 10.1097/01.ASN.0000048716.42876.14, 12538745.
35. Schmitt WH, Birck R, Heinzel PA, Göbel U, Choi M, Warnatz K, Peter HH, van der Woude FJ. Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients. Nephrol Dial Transplant 2005, 20:1083-1092. 10.1093/ndt/gfh763, 15827051.
36. Flossmann O, Baslund B, Bruchfeld A, Cohen Tervaert JW, Hall C, Heinzel P, Hellmich B, Luqmani RA, Nemoto K, Tesar V, Jayne DR. Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Ann Rheum Dis 2009, 68:1125-1130. 10.1136/ard.2008.092429, 18713783.
37. Gores PF. Deoxyspergualin: clinical experience. Transplant Proc 1996, 28:871-872.
38. Ramos EL, Nadler SG, Grasela DM, Kelley SL. Deoxyspergualin: mechanism of action and pharmacokinetics. Transplant Proc 1996, 28:873-875.
39. Lorenz HM, Grunke M, Wendler J, Heinzel PA, Kalden JR. Safety of 15-deoxyspergualin in the treatment of glomerulonephritis associated with active systemic lupus erythematosus. Ann Rheum Dis 2005, 64:1517-1519. 10.1136/ard.2005.035329, 1755225, 16162907.
40. Fessler BJ. Infectious diseases in systemic lupus erythematosus: risk factors, management and prophylaxis. Best Pract Res Clin Rheumatol 2002, 16:281-291. 10.1053/berh.2001.0226, 12041954.
41. Hallan SI, Ritz E, Lydersen S, Romundstad S, Kvenild K, Orth SR. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 2009, 20:1069-1077. 10.1681/ASN.2008070730, 2678033, 19357254.
42. Jónsdóttir T, Gunnarsson I, Risselada A, Henriksson EW, Klareskog L, van Vollenhoven RF. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2008, 67:330-334.
43. Vigna-Perez M, Hernández-Castro B, Paredes-Saharopulos O, Portales-Pérez D, Baranda L, Abud-Mendoza C, González-Amaro R. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006, 8:R83. 10.1186/ar1954, 1526618, 16677395.